KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA)

KLP Kapitalforvaltning AS acquired a new position in Savara Inc (NASDAQ:SVRA) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 13,200 shares of the company’s stock, valued at approximately $41,000.

A number of other large investors also recently modified their holdings of SVRA. Rosalind Advisors Inc. purchased a new stake in shares of Savara in the fourth quarter worth about $8,151,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Savara by 238.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock valued at $3,865,000 after purchasing an additional 642,259 shares during the period. State Street Corp grew its holdings in Savara by 15.7% during the 3rd quarter. State Street Corp now owns 4,138,276 shares of the company’s stock valued at $17,546,000 after purchasing an additional 560,242 shares in the last quarter. Geode Capital Management LLC increased its stake in Savara by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock worth $11,564,000 after buying an additional 264,825 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Savara during the 4th quarter valued at approximately $798,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Price Performance

Shares of NASDAQ SVRA opened at $2.92 on Friday. Savara Inc has a fifty-two week low of $2.26 and a fifty-two week high of $5.33. The stock has a market cap of $504.09 million, a P/E ratio of -6.79 and a beta of 0.52. The firm’s 50-day simple moving average is $2.72 and its 200 day simple moving average is $3.13. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last released its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. Equities analysts expect that Savara Inc will post -0.45 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on SVRA. Wells Fargo & Company began coverage on Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Savara in a report on Friday, March 28th. Finally, JMP Securities restated a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and an average target price of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.